OncoMatch/Clinical Trials/NCT06252298
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
Is NCT06252298 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SCTC21C for relapsed or refractory hematologic malignancies.
Treatment: SCTC21C — The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD38 overexpression (positive by immunohistochemistry or flow cytometry)
CD38+（confirmed by immunohistochemistry or flow cytometry）
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapies
Standard therapies failed or are unavailable or intolerant
Cannot have received: antineoplastic drug (except hormones)
other antineoplastic drug (except hormones) or radiotherapy within four weeks prior to the first dose of study drug
Cannot have received: radiotherapy
other antineoplastic drug (except hormones) or radiotherapy within four weeks prior to the first dose of study drug
Cannot have received: immunotherapy
immunotherapy or anti-CD38 monoclonal antibody within 6 months
Cannot have received: anti-CD38 monoclonal antibody
immunotherapy or anti-CD38 monoclonal antibody within 6 months
Lab requirements
Blood counts
platelet≥75x10^9 /l, absolute neutrophil counts ≥ 1.0x10^9 /l, hemoglobin ≥ 8.0 g/dl
Kidney function
basically normal kidney function
Liver function
basically normal liver function
Cardiac function
basically normal heart function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify